Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
KKYORIN Pharmaceutical Co.,Ltd. logo
4569TSE Prime

KYORIN Pharmaceutical Co.,Ltd.

杏林製薬 Yahoo Finance

Recent & upcoming events

Jul 30
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Jun 18
Shareholder meeting Time TBD
Shareholders' meeting
Add to Google Calendar
May 12
Earnings 2:00
FY earnings announcement (scheduled)
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Oct 15
Est.
Earnings 2:00 approx.
Q2 earnings
Add to Google Calendar
2027
Jan 7
Est.
Earnings 1:00 approx.
Q3 earnings
Add to Google Calendar
Mar 25
Est.
Earnings 2:00 approx.
Q3 earnings
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Mar 29
Est.
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
Jun 10
Est.
Earnings 2:00 approx.
Full-year earnings
Add to Google Calendar

KPI highlights

FY26
Revenue ¥126.26B YoY -2.9%
Operating income ¥3.57B margin 2.8%
Net income ¥3.45B YoY -62.1%
EPS ¥60 YoY -62.0%
P/E —
ROE 2.5% Equity ratio 73% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company guidance

FY2027/03 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥121.80B -3.5%
Operating income ¥2.00B -43.9%
Net income ¥1.50B -56.5%
EPS ¥26 -56.5%

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY24 Q2FY25 Q2
Revenue ¥27.85B¥27.08B¥32.33B¥32.27B——
Operating income ¥711M¥434M¥3.32B¥1.55B——
Net income ¥676M¥1.08B¥2.16B¥1.41B——
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2021–2026）

事業法人 26.2%国内機関 14.2%海外機関 3.4%個人 3.6%未開示 52.6%202120222023202420252026
事業法人国内機関海外機関個人未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

日本マスタートラスト信託銀行株式会社 10.4%日本マスタートラスト信託銀行株式会社（信託口）株式会社マイカム 8.9%株式会社マイカム株式会社ルキウス 4.8%株式会社ルキウス株式会社日本カストディ銀行（信託口） 3.8%株式会社日本カストディ銀行（信託口）キョーリン製薬グループ持株会 3.6%キョーリン製薬グループ持株会株式会社バンリーナ 3.4%株式会社バンリーナ株式会社アーチァンズ 3.4%株式会社アーチァンズ株式会社ルーチェス 3%株式会社ルーチェス科研製薬株式会社 2.8%科研製薬株式会社202120222023202420252026

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
日本マスタートラスト信託銀行株式会社（信託口） 6,053,000 10.4% Yuho (EDINET)
株式会社マイカム 5,178,000 8.9% Yuho (EDINET)
株式会社ルキウス 2,817,000 4.8% Yuho (EDINET)
株式会社日本カストディ銀行（信託口） 2,207,000 3.8% Yuho (EDINET)
キョーリン製薬グループ持株会 2,090,000 3.6% Yuho (EDINET)
BBH FOR THE ADVISORS’ INNERCIRCLE FUND II／KOPERNIK GLO ALL－CAP FUND 1,995,000 3.4% Yuho (EDINET)
株式会社バンリーナ 1,950,000 3.4% Yuho (EDINET)
株式会社アーチァンズ 1,950,000 3.4% Yuho (EDINET)
株式会社ルーチェス 1,760,000 3.0% Yuho (EDINET)
科研製薬株式会社 1,602,000 2.8% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

6/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 1.8%
✓ Positive operating cash flow ¥6.38B
✗ ROA improved YoY 4.7% → 1.8%
✓ Operating CF exceeds net income (accrual quality) OCF ¥6.38B / net income ¥3.45B
✓ Equity ratio improved* Substitute for the original “decrease in long-term debt” 70.4% → 72.9%
✓ Current ratio improved 3.88× → 4.60×
✓ No dilution (shares outstanding did not increase) 64,607,936 → 59,945,641
✗ Gross margin improved 45.8% → 40.9%
✗ Asset turnover improved 0.67× → 0.65×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY26
Equity ratio 72.9%
Current ratio 4.6×
Years of positive operating CF 10 of last 10 yrs
Payout ratio 79%
Latest fiscal year result Profit (net income ¥3.45B)

Performance history

Last 10 years
0億円325億円650億円976億円1,301億円 FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Income & assets

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Revenue 1,1541,1061,1361,1001,0291,0551,1331,1951,3011,263
Operating income 10488.289.775.057.950.151.260.112635.7
Ordinary income 10993.594.481.864.555.758.366.013240.3
Net income 73.165.768.761.561.339.347.253.290.934.5
Total assets 1,9271,9841,7301,7121,6711,7191,7601,7771,9361,955
Equity 1,5781,6331,2341,2271,2471,2451,2551,3081,3631,424

Indicators & cash flow

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
EPS ¥99¥89¥105¥107¥107¥69¥82¥93¥158¥60
ROE 4.6%4.1%4.8%5.0%5.0%3.2%3.8%4.2%6.8%2.5%
Operating CF 1641053.4077.451.963.520.115.535.163.8
Investing CF -131-60.4149-29.4-42.6-25.6-62.8-31.9-63.2-16.4
Financing CF -57.2-37.4-273-51.2-49.2-41.1-33.6-33.539.5-79.6
FCF 32.444.215348.09.3037.9-42.7-16.4-28.247.4

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data